Form 4: Replimune Director Paolo Pucci Granted 44,500 Options

Replimune Group, Inc. director Paolo Pucci received a grant of 44,500 stock options with an exercise price of $7.61, set to vest in April 2027.

Summary

• Paolo Pucci, a member of the Board of Directors, was granted 44,500 stock options on April 1, 2026.
• The options carry an exercise price of $7.61 per share, matching the market conditions at the time of the grant.
• The grant is scheduled to vest in full on April 1, 2027, provided the director remains with the company.
• The options have a ten-year term, expiring on April 1, 2036.
• The disclosure was filed with the SEC on April 7, 2026, which was noted as a late filing due to an administrative error.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. While insider equity grants are generally positive for alignment, the late filing is a minor negative mark on corporate secretarial diligence.

Positives

• Insider alignment with shareholders through equity-based compensation.
• The director now holds a total of 44,500 derivative securities following this transaction.
• Long-term commitment indicated by a 10-year expiration window on the options.

Negatives

• The filing was submitted late, which represents a minor regulatory compliance oversight.
• Potential for future share dilution when the options are exercised.

Risks

• The value of the compensation is entirely dependent on the stock price exceeding the $7.61 exercise price.
• Administrative errors in SEC filings can occasionally signal internal control weaknesses, though this appears to be an isolated incident.

Future Outlook

The grant incentivizes the director to contribute to the company's growth over the next year to ensure the options are 'in the money' by the vesting date in April 2027.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity grants are a standard component of director compensation in the biotechnology sector, serving to preserve cash while aligning board interests with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of 44,500 options is consistent with mid-cap biotech board compensation structures.
• A one-year cliff vesting schedule is a common practice for annual director equity awards in the NASDAQ Biotechnology Index.

Related Party Transactions

• Grant of 44,500 stock options to Director Paolo Pucci as part of standard compensation.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.
• The Board of Directors maintains its skin in the game regarding company performance.

Next Steps

• Vesting of the options on April 1, 2027.

Key Dates

Recommendation

This filing represents a routine compensation event for a director and does not provide new information regarding the company's clinical pipeline or financial health that would warrant a change in investment thesis.

Keywords

Replimune Group, REPL, Paolo Pucci, Stock Options, Insider Trading, Director Compensation, Biotechnology